CMSC International has released a research report initiating coverage on RIBOLIFE-B (06938) with an "Add" rating and a target price of HK$105. The firm is optimistic about the company's core asset, RBD4059, which is positioned as the world's first small interfering RNA (siRNA) anticoagulant targeting coagulation factor XI. This product has the potential to become a new generation of long-acting anticoagulation therapy.

The report highlights that the global anticoagulant market is projected to reach a future capacity of up to $60 billion. Bayer's Asundexian, the world's first small molecule targeting coagulation factor XIa, has already submitted a marketing application to the US FDA in May and is expected to launch by year-end. This development is anticipated to reshape the global competitive landscape for anticoagulants.

CMSC International currently forecasts that RIBOLIFE-B will generate revenues of approximately RMB 442 million, RMB 115 million, and RMB 147 million for the years 2026, 2027, and 2028, respectively. The firm also predicts the company will record annual net losses of around RMB 288 million, RMB 38 million, and RMB 335 million for the same periods.